|Calculated MW||This protein is fused with 6×His tag at the C-terminus, has a calculated MW of 26.7 kDa. The predicted N-terminus is Leu 20. DTT-reduced Protein migrates as 43-60 kDa due to glycosylation.|
|Other Names||CD86, B7-2, B70, CD28LG2, LAB72, MGC34413|
|Results||Measured by its binding ability in a functional ELISA. Immobilized human B7-2/CD86 at 20 µg/ml (100 µl/well) can bind human CD28 with a linear ranger of 32 - 500 ng/ml.|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose is added as protectants before lyophilization.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.
Azuma M.,et al.Nature 366:76-79(1993).
Freeman G.J.,et al.Science 262:909-911(1993).
Magistrelli G.,et al.Biochem. Biophys. Res. Commun. 280:1211-1215(2001).
Halleck A.,et al.Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
Livingston R.J.,et al.Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases.
If you have any additional inquiries please email technical services at email@example.com.